Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101 + Targeted and Immunotherapy for BCLC Stage C HCC
NCT06685354Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Oncorine in hepatocellular carcinoma (HCC), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
Oncorine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06685354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685354.